FCGBP

Across TCGA pan-cancer cohorts, FCGBP Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated FCGBP data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher FCGBP Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FCGBP expression acts as an unfavorable survival marker, although some lineages such as BLCA and LUSC show a favorable association.

LUAD, HNSC, and BLCA are the cancer types where FCGBP Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.159	0.684	<.001	26	view →
HNSC	OS	Median	All	0.220	0.606	.015	15	view →
BLCA	OS	Median	II,III,IV	0.910	0.417	.015	14	view →
LUSC	DFS	Median	III,IV	0.668	0.316	.004	10	view →
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →
SKCM	OS	Median	All	0.769	0.879	.010	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

FCGBP–LUAD (OS)

Open the LUAD breakdown →